Definium Therapeutics, Inc. (MNMD)
NASDAQ · Healthcare
Definium Therapeutics, Inc. Shareholder Equity 2020–2025
Definium Therapeutics, Inc. annual shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Definium Therapeutics, Inc. shareholder equity as of December 31, 2025: 332.3M, a 37.64% increase year-over-year.
- Definium Therapeutics, Inc. shareholder equity for 2025 were 332.3M, a 37.64% increase from 2024.
- Definium Therapeutics, Inc. shareholder equity for 2024 were 241.4M, a 209.02% increase from 2023.
- Definium Therapeutics, Inc. shareholder equity for 2023 were 78.1M, a 48.23% decrease from 2022.
- Definium Therapeutics, Inc. shareholder equity for 2022 were 150.9M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Definium Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $332 |
| 2024 | $241 |
| 2023 | $78 |
| 2022 | $151 |
| 2021 | $152 |
| 2020 | $76 |
Definium Therapeutics, Inc. Shareholder Equity — FAQ
Definium Therapeutics, Inc. (MNMD) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MNMD's shareholder equity history?
The chart and table above show Definium Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.